GLP-1 receptor agonists and emerging incretin multi-agonists (dual/triple receptor agonists) exert coordinated effects across what the authors term the 'cardiohepatic-metabolic axis' in metabolic dysfunction-associated steatohepatitis (MASH). Mechanistically, these agents suppress appetite, increase energy expenditure, and modulate AMPK, mTOR, and NLRP3 inflammasome signaling to reduce hepatic steatosis and inflammation. Three landmark trials anchor the clinical case: ESSENCE (MASH histological resolution), STEP-HFpEF (obesity-related heart failure with preserved ejection fraction), and SELECT (major adverse cardiovascular event reduction in overweight patients with established CVD).
What makes this analysis worth attention is the underlying convergence it reveals: MASH is no longer a liver-isolated condition but a systemic cardiometabolic disease demanding multi-organ pharmacology. GLP-1-based agents happen to hit several pathological nodes simultaneously — a rare alignment of mechanism and clinical need. However, the authors themselves flag a critical interpretive hazard: SELECT's cardiovascular outcome data involved patients with obesity and CVD, not biopsy-confirmed MASH, meaning direct extrapolation overstates the proven benefit in that specific population. The AMPK/mTOR/NLRP3 mechanistic narrative, while compelling, remains incompletely validated in humans at the pathway level. As a review synthesizing existing trials rather than generating new data, the analysis is confirmatory and clarifying rather than paradigm-shifting — but its practical value lies in reframing MASH management as inherently cardiometabolic, which should influence clinical thinking now.